The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Fc Protein and Glyco-engineered Antibodies Market: Focus on Type of Fc Engineering and Therapeutics (3rd edition), 2021-2030

  • Lowest Price Guaranteed From USD 5,499

  • Published
    July 2021

  • Pages
    290

  • View Count
    443

Example Insights

Fc-Protein-Engineered-and-Glycoengineered-Antibodies-Market-Context 	Fc-Protein-Engineered-and-Glycoengineered-Antibodies-Market-Distribution-by-Company-Size-and-Year-of-Establishment Fc-Protein-Engineered-and-Glycoengineered-Antibodies-Market-Distribution-by-Therapeutic-Area
Fc-Protein-Engineered-and-Glycoengineered-Antibodies-Market-Grant-Analysis Fc-Protein-Engineered-and-Glycoengineered-Antibodies-Market-Grant-Analysis Fc-Protein-Engineered-and-Glycoengineered-Antibodies-Market-Clinical-Research-Landscape
Fc-Protein-Engineered-and-Glycoengineered-Antibodies-Market-Parnerships-and-Collaborations Fc-Protein-Engineered-and-Glycoengineered-Antibodies-Market-Distribution-by-Geography Fc-Protein-Engineered-and-Glycoengineered-Antibodies-Market-Future-Forecast

 

Overview

With close to 100 approved monoclonal antibodies, and over 550 molecules in the clinical pipeline, antibody based pharmacological interventions have become one of the fast growing segment of the biopharmaceutical industry. In fact, these interventions are anticipated to generate a cumulative sales of USD 300 billion by 2025. Further, within the antibody therapeutics industry, engineered antibodies, developed by modifying the fragment crystallizable (Fc) region, have garnered significant interest over the past few years. The modifications (such as glycoengineering, protein engineering or isotype chimerism) in the Fc region of an antibody have shown to augment the various effector functions, such as antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP) activity and / or the half-life of the molecule. Moreover, several Fc engineering technologies enable the suppression of the effector functions in certain pathways, and are being actively exploited for development of anti-cancer antibodies. 

Over time, a substantial body of evidence has validated the therapeutic applications of Fc engineering platforms, which, in turn, has led to the establishment of numerous strategic partnerships (focused on therapy development and clinical research) and significant investment into the innovator companies. The consistent research efforts in this domain have translated into the emergence of two blockbuster drugs, namely Gazyva® (for Chronic Lymphocytic Leukemia) and POTELEGIO® (for Sézary syndrome) and several other Fc engineered antibody products, including Margenza™, MONJUVI® and SKYRIZI™ that received approval in the past few years. More recently, in 2021, two Fc engineered antibodies, namely Sotrovimab and Etesevimab, got approved for the treatment of COVID-19. Further, there are several drugs in the development pipeline, which are being investigated by various small and established pharmaceutical companies. The promising clinical results, and ongoing technical developments, coupled to the growing interest of biopharmaceutical developers, are anticipated to give the required impetus to the push pipeline products to higher stages of development, and commercialization. We believe that the market is likely to evolve at a commendable pace over the next decade.

Scope of the Report

The ‘Fc Protein and Glyco-engineered Antibodies Market: Focus on Type of Fc Engineering and Therapeutics (3rd edition), 2021-2030’ report features an extensive study on the current and future potential of Fc engineered antibodies. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geographies. Amongst other elements, the report includes:

  • A detailed review of the Fc protein and glyco-engineered antibodies that are currently marketed and are in different stages of development. It features a detailed analysis of marketed / development programs, based on several relevant parameters, such as phase of development (marketed, clinical and preclinical), target disease indication (atopic dermatitis, gastric cancer, head and neck cancer, non-small cell lung cancer, psoriasis, solid tumors and others), target therapeutic area (autoimmune disorders, infectious diseases, oncological disorders and others), target gene (CD20, CD30, PD-L1  and others), type of antibody (IgG1, IgG2, IgG2/4 and others), type of Fc engineering, and impact of Fc engineering (enhanced effector function, reduced effector function and enhanced serum half-life), route of administration (intravenous, subcutaneous and others) and type of therapy (monotherapy and combination therapy).
  • A detailed review of the companies developing Fc engineered antibodies, along with information on their year of establishment, company size, and location of headquarters.
  • Elaborate profiles of the key players engaged in the development of Fc engineered antibodies. Each profile includes a brief overview of the company, its financial information (if available), information on product portfolio, recent developments and an informed future outlook.
  • An analysis of the partnerships that have been established in this domain, since 2016, covering research agreements, product / technology licensing agreements, mergers and acquisitions, asset purchase agreements, R&D agreements, clinical trial agreements, product development and commercialization agreements, and other relevant type of deals.
  • An in-depth analysis of completed, ongoing, and planned clinical studies for evaluating different Fc engineered antibodies, based on several relevant parameters, such as trial registration year, current trial status, phase of development, enrolled patient population, study design, leading industry and non-industry players (in terms of number of trials conducted), study focus, type of drug molecule, target disease indication, therapeutic area and key geographical regions.
  • An in-depth analysis of the grants awarded to various research institutes for projects related to Fc protein and glyco-engineered antibodies, in the period between 2016-2021, based on parameters, such as year of award, amount awarded, administering institute center, support period, type of grant application, purpose of grant award, activity code, emerging focus areas of the grants, popular NIH departments, type of recipient organization, popular recipient organizations, popular program officers and regional distribution of recipient organizations.
  • An in-depth analysis of around 6,500 patents related to Fc engineering that have been filed / granted, since 2016, highlighting the key trends associated with these patents, across parameters, such as type of patent, publication year and application year, regional applicability, IPCR symbols, emerging focus areas, inventor information, leading patent assignees (in terms of number of patents filed / granted), and patent valuation.

One of the key objectives of the report was to estimate the existing and future growth potential of Fc protein and glyco-engineered antibodies market, over the coming decade. Based on multiple parameters, such as target patient population, likely adoption rates and expected pricing, we have provided informed estimates on the evolution of the market for the period 2021-2030. The report features the likely distribution of the current and forecasted opportunity across [A] type of Fc engineering (Fc protein and glyco-engineered) [B] type of therapy (monotherapy and combination therapy) [C] therapeutic area (autoimmune disorders, oncological disorders, infectious diseases and others), [D] route of administration (intravenous, subcutaneous and others), and [E] key geographical regions (North America, Europe, Asia-Pacific and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the anticipated industry’s growth. 

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading industry and non-industry players engaged in the development of Fc protein and glyco-engineered antibodies?
  • Which are the key disease indications being targeted by Fc engineered antibodies?
  • Which partnership models are commonly adopted by stakeholders engaged in this domain?
  • Which geographies are the most active in conducting clinical trials on Fc protein and glyco-engineered antibodies? 
  • Which are the leading administering institutes supporting the research related to Fc protein and glyco-engineered antibodies? 
  • How has the intellectual property landscape in this market evolved over the years?
  • Which key factors are likely to influence the evolution of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the market for Fc protein and glyco-engineered antibodies and its likely evolution in the short-mid-term and long term.

Chapter 3 provides a general introduction to antibodies, including information on structure of antibodies, history of antibody discovery, antibody isotypes, mechanism of action of antibodies. Further, the chapter features a brief overview of the Fc region and effector functions,  type of Fc receptors, engineering of the region along with details on glycoengineering, protein engineering and isotype chimerism. Furthermore, the chapter provides an overview of the upcoming future trends, which, we believe, are likely to influence the growth of the Fc engineered antibodies market.

Chapter 4 provides information on over 125 marketed / development programs that are designed for the treatment of various indications, including autoimmune disorders, oncological disorders and others. It features a detailed analysis of  Fc protein and glyco-engineered antibodies, based on several relevant parameters, such as phase of development (marketed, clinical and preclinical), target therapeutic area (autoimmune disorders, infectious diseases, oncological disorders and others), target gene (CD20, CD30, PD-L1  and others), type of therapy (monotherapy and combination therapy), route of administration (intravenous, subcutaneous and others), type of antibody (IgG1, IgG2, IgG2/4 and others), type of Fc engineering, and impact of Fc engineering (enhanced effector function, reduced effector function and enhanced serum half-life).

Chapter 5 includes tabulated profiles of prominent players engaged in the development of Fc engineered antibodies. Each profile features a brief overview of the company, its financial information (if available), information on product portfolio, recent developments and an informed future outlook.

Chapter 6 provides a detailed analysis of the recent collaborations (established since 2016) focused on Fc engineered antibodies, based on relevant parameters, such as the year of agreement, type of agreement, therapeutic area, type of Fc engineering, and regional distribution of partnerships.

Chapter 7 provides an in-depth analysis of completed, ongoing, and planned clinical studies of Fc engineered antibodies, based on several relevant parameters, such as current trial status, trial registration year, drug molecule, phase of development, enrolled patient population, study design, leading industry and non-industry players (in terms of number of trials conducted), study focus, target disease indication, therapeutic area and key geographical regions.

Chapter 8 features an in-depth analysis of grants awarded to various research institutes for  projects related to Fc protein and glyco-engineered antibodies, in the period between 2016- 2021, based on several parameters, such as year of award, amount awarded, administering institute center, support period, type of grant application, purpose of grant award, activity code, emerging focus areas of the grants, popular NIH departments, type of recipient organization, popular recipient organizations, popular program officers and regional distribution of recipient organizations.

Chapter 9 features an elaborate analysis of around 6,500 patents related to Fc engineering that have been filed / granted, since 2016, highlighting the key trends associated with these patents, across parameters, such as type of patent, publication year and application year, regional applicability, IPCR symbols, emerging focus areas, inventor information, leading patent assignees (in terms of number of patents filed / granted) and patent valuation.

Chapter 10 presents an insightful market forecast analysis, highlighting the likely growth of Fc protein and glyco-engineered antibodies till the year 2030.  For this purpose, we have segmented the future opportunity across [A] type of Fc engineering (Fc protein and glyco-engineering) [B] type of therapy (monotherapy and combination therapy) [C] therapeutic area (autoimmune disorders, oncological disorders, infectious diseases and others), [D] route of administration (intravenous, subcutaneous and others) [E] key geographical regions (North America, Europe, Asia-Pacific and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the anticipated industry’s growth.   

Chapter 11 is a summary of the overall report, which presents insights on the contemporary market trends and the likely evolution of the Fc protein and glyco-engineered antibodies market. 

Chapter 12 is an appendix, that contains tabulated data and numbers for all the figures included in the report.

Chapter 13 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Structure of Antibodies
3.3. History of Antibody Discovery
3.4. Antibody Isotypes 
3.5. Mechanism of Action of Antibodies 
3.6. Fc Region and Effector Functions
3.6.1. Types of Fc Receptors
3.6.2. Engineering of the Fc Region
3.6.2.1. Glycoengineering
3.6.2.2. Protein Engineering
3.6.2.3. Isotype Chimerism

3.7. Future of Engineered Antibodies

4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Fc Protein Engineered and Glycoengineered Antibodies: Pipeline Review
4.2.1. Analysis by Phase of Development 
4.2.2. Analysis by Target Disease Indication
4.2.3. Analysis by Therapeutic Area
4.2.4. Analysis by Target Gene
4.2.5. Analysis by Type of Antibody
4.2.6. Analysis by Type of Fc Engineering
4.2.7. Analysis by Impact of Fc Engineering
4.2.8. Analysis by Route of Administration
4.2.9. Analysis by Type of Therapy
4.2.10. Popular Fc Engineering Technologies: Analysis by Number of Development Programs

4.3. Fc Protein Engineered and Glycoengineered Antibodies: List of Developers
4.3.1 Analysis by Year of Establishment
4.3.2 Analysis by Company Size
4.3.3 Analysis by Location of Headquarters

5. COMPANY PROFILES
5.1. Chapter Overview
5.2. AbbVie
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. Drug Portfolio
5.2.3.1 Drug Profile: Skyrizi

5.2.4 Recent Developments and Future Outlook

5.3. Alexion Pharmaceuticals
5.3.1. Company Overview
5.3.2. Financial Information
5.3.3. Drug Portfolio
5.3.3.1. Drug Profile: Soliris
5.3.3.2. Drug Profile: Ultomiris

5.3.4. Recent Developments and Future Outlook

5.4. AstraZeneca
5.4.1. Company Overview
5.4.2. Financial Performance
5.4.3. Drug Portfolio
5.4.3.1. Drug Profile: Imfinzi
5.4.3.2. Drug Profile: Fasenra
5.4.3.3. Drug Profile: Anifrolumab
5.4.3.4. Drug Profile: Nirsevimab

5.4.3 Recent Developments and Future Outlook

5.5. Genentech
5.5.1. Company Overview
5.5.2. Financial Information
5.5.3. Drug Portfolio
5.5.3.1. Drug Profile: Gazyva
5.5.3.2. Drug Profile: Tecentriq
5.5.3.3. Drug Profile: Ocrevus

5.5.4 Recent Developments and Future Outlook

5.6. MacroGenics
5.6.1. Company Overview
5.6.2. Financial Information
5.6.3. Drug Portfolio
5.6.3.1. Drug Profile: Margenza
5.6.3.2. Drug Profile: Enoblituzumab

5.6.4. Recent Developments and Future Outlook

5.7. Kyowa Kirin
5.7.1. Company Overview
5.7.2. Financial Portfolio
5.7.3. Drug Portfolio
5.7.3.1. Drug Profile: POTELIGEO

5.7.4. Recent Developments and Future Outlook

6. PARTNERSHIPS AND COLLABORATIONS
6.1. Chapter Overview
6.2. Partnership Models
6.3. Fc Protein Engineered and Glycoengineered Antibodies: List of Partnerships and Collaborations
6.3.1. Analysis by Year of Partnership
6.3.2. Analysis by Type of Partnership
6.3.3. Analysis by Year of Partnership and Type of Partner
6.3.4. Analysis by Type of Partnership and Type of Partner
6.3.5. Most Active Players: Analysis by Number of Partnerships
6.3.6. Analysis by Therapeutic Area
6.3.7. Analysis by Type of Fc Engineering
6.3.8. Analysis by Type of Partnership, Therapeutic Area and Type of Fc Engineering
6.3.9. Regional Analysis
6.3.10. International and Intracontinental Agreements

7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Fc Protein Engineered and Glycoengineered Antibodies: Clinical Trials
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Trial Registration Year and Trial Status
7.3.3. Analysis by Trial Registration Year and Enrolled Patient Population
7.3.4. Analysis by Trial Phase
7.3.5. Analysis by Trial Phase and Enrolled Patient Population
7.3.6. Analysis by Study Design
7.3.7. Analysis by Type of Sponsor / Collaborator
7.3.8. Most Active Industry Players: Analysis by Number of Registered Trials
7.3.9. Most Active Non-Industry Players: Analysis by Number of Registered Trials
7.3.10. Analysis by Trial Focus
7.3.11. Analysis by Type of Drug Molecule
7.3.12. Analysis by Key Indications
7.3.13. Analysis by Therapeutic Area
7.3.14. Geographical Analysis by Number of Clinical Trials
7.3.15. Geographical Analysis by Number of Clinical Trials and Trial Status
7.3.16. Geographical Analysis by Enrolled Patient Population
7.3.17. Geographical Analysis by Enrolled Patient Population and Trial Status

8. ACADEMIC GRANTS ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Fc Protein Engineered and Glycoengineered Antibodies: Academic Grants Analysis 
8.3.1. Analysis by Year of Grant Award
8.3.2. Analysis by Amount Awarded
8.3.3. Analysis by Administering Institute Center
8.3.4. Analysis by Funding Institute Center
8.3.5. Analysis by Support Period
8.3.6. Analysis by Funding Institute Center and Support Period
8.3.7. Analysis by Type of Grant Application
8.3.8. Analysis by Purpose of Grant Award
8.3.9. Analysis by Activity Code
8.3.10. Word Cloud Analysis: Emerging Focus Areas
8.3.11. Analysis by Study Section Involved
8.3.12. Popular NIH Departments: Analysis by Number of Grants
8.3.13. Prominent Program Officers: Analysis by Number of Grants
8.3.14. Analysis by Type of Recipient Organization
8.3.15. Popular Recipient Organizations: Analysis by Number of Grants
8.3.16. Regional Distribution of Recipient Organizations

9. PATENT ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Fc Protein Engineered and Glycoengineered Antibodies: Patent Analysis
9.3.1. Analysis by Publication Year
9.3.2. Analysis by Issuing Authority / Patent Offices Involved
9.3.3. Analysis by CPC Symbols
9.3.4. Word Cloud: Emerging Focus Areas
9.3.5. Analysis by Type of Organization
9.3.6. Leading Players: Analysis by Number of Patents
9.3.7. Analysis by Patent Valuation
9.3.8. Leading Patents by Number of Citations

10. MARKET FORECAST AND OPPORTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Key Assumptions and Forecast Methodology
10.3. Global Fc Protein and Glycoengineered Antibodies Market, 2021-2030
10.3.1. Fc Protein Engineered and Glycoengineered Antibodies Market, 2021-2030: Distribution by Type of Fc Engineering
10.3.1.1. Fc Protein Engineered and Glycoengineered Antibodies Market for Fc Protein Engineered Antibodies, 2021-2030
10.3.1.2. Fc Protein Engineered and Glycoengineered Antibodies Market for Fc Glycoengineered Antibodies, 2021-2030
10.3.2. Fc Protein Engineered and Glycoengineered Antibodies Market, 2021-2030: Distribution by Type of Therapy
10.3.2.1. Fc Protein Engineered and Glycoengineered Antibodies Market for Monotherapy, 2021-2030
10.3.2.2. Fc Protein Engineered and Glycoengineered Antibodies Market for Combination therapy, 2021-2030
10.3.3. Fc Protein Engineered and Glycoengineered Antibodies Market, 2021-2030: Distribution by Therapeutic Area
10.3.3.1. Fc Protein Engineered and Glycoengineered Antibodies Market for Oncological Disorders, 2021-2030
10.3.3.2. Fc Protein Engineered and Glycoengineered Antibodies Market for Rare Disorders, 2021-2030
10.3.3.3. Fc Protein Engineered and Glycoengineered Antibodies Market for Dermatological Disorders, 2021-2030
10.3.3.4. Fc Protein Engineered and Glycoengineered Antibodies Market for Autoimmune Disorders, 2021-2030
10.3.3.5. Fc Protein Engineered and Glycoengineered Antibodies Market for Infectious Diseases, 2021-2030
10.3.3.6. Fc Protein Engineered and Glycoengineered Antibodies Market for Gastrointestinal Disorders, 2021-2030
10.3.3.7. Fc Protein Engineered and Glycoengineered Antibodies Market for Neurological Disorders, 2021-2030
10.3.3.8. Fc Protein Engineered and Glycoengineered Antibodies Market for Pulmonary Disorders, 2021-2030
10.3.4. Fc Protein Engineered and Glycoengineered Antibodies Market, 2021-2030: Distribution by Route of Administration
10.3.4.1. Fc Protein Engineered and Glycoengineered Antibodies Market for Intravenous Route, 2021-2030
10.3.4.2. Fc Protein Engineered and Glycoengineered Antibodies Market for Subcutaneous Route, 2021-2030
10.3.4.3. Fc Protein Engineered and Glycoengineered Antibodies Market for Other Routes of Administration, 2021-2030
10.3.5. Fc Protein Engineered and Glycoengineered Antibodies Market, 2021-2030: Distribution by Geography
10.3.5.1. Fc Protein Engineered and Glycoengineered Antibodies Market in North America, 2021-2030
10.3.5.2. Fc Protein Engineered and Glycoengineered Antibodies Market in Europe, 2021-2030
10.3.5.3. Fc Protein Engineered and Glycoengineered Antibodies Market in North America, 2021-2030
10.3.5.4. Fc Protein Engineered and Glycoengineered Antibodies Market in Asia-Pacific, 2021-2030
10.3.6. Global Fc Protein and Glycoengineered Antibodies Market (For Clinical Late-Stage Products), 2021-2030
10.3.7. Global Fc Protein and Glycoengineered Antibodies Market (For Commercialized Products), 2021-2030

11. CONCLUDING REMARKS

12. APPENDIX 1: TABULATED DATA

13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Basic Structure of an Antibody
Figure 3.2 Historical Timeline of Antibody Development
Figure 3.3 Functions of Antibodies
Figure 4.1 Fc Protein Engineered and Glycoengineered Antibodies: Distribution by Phase of Development
Figure 4.2 Fc Protein Engineered and Glycoengineered Antibodies: Distribution by Target Disease Indication
Figure 4.3 Fc Protein Engineered and Glycoengineered Antibodies: Distribution by Therapeutic Area
Figure 4.4 Fc Protein Engineered and Glycoengineered Antibodies: Distribution by Target Gene
Figure 4.5 Fc Protein Engineered and Glycoengineered Antibodies: Distribution by Type of Antibody
Figure 4.6 Fc Protein Engineered and Glycoengineered Antibodies: Distribution by Type of Fc Engineering
Figure 4.7 Fc Protein Engineered and Glycoengineered Antibodies: Distribution by Impact of Fc Engineering
Figure 4.8 Fc Protein Engineered and Glycoengineered Antibodies: Distribution by Route of Administration
Figure 4.9 Fc Protein Engineered and Glycoengineered Antibodies: Distribution by Type of Therapy
Figure 4.10 Popular Fc Engineering Technologies: Distribution by Number of Development Programs
Figure 4.11 Fc Protein and Glycoengineered Antibodies Developers: Distribution by Year of Establishment
Figure 4.12 Fc Protein and Glycoengineered Antibodies Developers: Distribution by Company Size
Figure 4.13 Fc Protein and Glycoengineered Antibodies Developers: Distribution by Location of Headquarters
Figure 4.14 World Map Representation: Analysis by Geography
Figure 5.1 AbbVie: Revenues, FY 2016 - Q1 FY 2021 (USD Billion)
Figure 5.2 Alexion Pharmaceuticals: Revenues, FY 2016 - Q1 FY 2021 (USD Billion)
Figure 5.3 AstraZeneca: Revenues, FY 2016 - Q1 FY 2021 (USD Billion)
Figure 5.4 Genentech / Roche: Revenues, FY 2016 - Q1 FY 2021 (USD Billion)
Figure 6.1 Partnerships and Collaborations: Cumulative Trend by Year of Partnership, 2016-2021
Figure 6.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 6.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2016-2021
Figure 6.4 Partnerships and Collaborations: Analysis by Year of Partnership and Type of Partner
Figure 6.5 Partnerships and Collaborations: Analysis by Type of Partnership and Type of Partner
Figure 6.6 Most Active Players: Distribution by Number of Partnerships
Figure 6.7 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 6.8 Partnerships and Collaborations: Distribution by Type of Fc Engineering
Figure 6.9 Partnerships and Collaborations: Distribution by Type of Partnership, Therapeutic Area and Type of Fc Engineering
Figure 6.10 Partnerships and Collaborations: Regional Distribution
Figure 6.11 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 7.1 Clinical Trial Analysis: Scope and Methodology
Figure 7.2 Clinical Trial Analysis: Distribution by Trial Status
Figure 7.3 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2001-2021
Figure 7.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2011-2021
Figure 7.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population
Figure 7.6 Clinical Trial Analysis: Distribution by Trial Phase
Figure 7.7 Clinical Trial Analysis: Distribution by Trial Phase and Enrolled Patient Population
Figure 7.8 Clinical Trial Analysis: Distribution by Study Design
Figure 7.9 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 7.10 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 7.11 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Figure 7.12 Clinical Trial Analysis: Word Cloud of Popular Keywords
Figure 7.13 Clinical Trial Analysis: Distribution by Type of Drug Molecule
Figure 7.14 Clinical Trial Analysis: Target Disease Indications
Figure 7.15 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 7.16 Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials
Figure 7.17 Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials and Trial Status
Figure 7.18 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Figure 7.19 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population and Trial Status
Figure 8.1 Grant Analysis: Cumulative Year-Wise Trend of Grants Awarded, 2019-2021
Figure 8.2 Grant Analysis: Distribution by Amount Awarded (USD Million), 2019-2021
Figure 8.3 Grant Analysis: Distribution by Funding Institute Center
Figure 8.4 Grant Analysis: Distribution by Support Period
Figure 8.5 Grant Analysis: Distribution by Funding Institute Center and Support Period
Figure 8.6 Grant Analysis: Distribution by Type of Grant Application
Figure 8.7 Grant Analysis: Distribution by Purpose of Grant Award
Figure 8.8 Grant Analysis: Distribution by Activity Code
Figure 8.9 Word Cloud: Emerging Focus Areas
Figure 8.10 Grant Analysis: Distribution by Study Section Involved
Figure 8.11 Popular NIH Departments: Distribution by Number of Grants
Figure 8.12 Prominent Program Officers: Distribution by Number of Grants
Figure 8.13 Grant Analysis: Distribution by Type of Recipient Organization
Figure 8.14 Popular Recipient Organizations: Distribution by Number of Grants
Figure 8.15 Grant Analysis: Regional Distribution of Recipient Organization
Figure 9.1 Patent Analysis: Distribution by Type of Patent
Figure 9.2 Patent Analysis: Cumulative Distribution by Publication Year, 2016-2021
Figure 9.3 Patent Analysis: Cumulative Distribution by Issuing Authority / Patent Offices Involved
Figure 9.4 Patent Analysis: Distribution by CPC Symbols
Figure 9.5 Patent Analysis: Emerging Focus Areas
Figure 9.6 Patent Analysis: Distribution by Type of Organization
Figure 9.7 Leading Industry Players: Distribution by Number of Patents
Figure 9.8 Leading Non-Industry Players: Distribution by Number of Patents
Figure 9.9 Leading Individual Assignees: Distribution by Number of Patents
Figure 9.10 Patent Analysis: Distribution of Patents by Age
Figure 10.1 Global Fc Protein and Glycoengineered Antibodies Market, 2021-2030
Figure 10.2 Global Fc Protein and Glycoengineered Antibodies Market, 2021 and 2030: Distribution by Type of Fc Engineering
Figure 10.3 Fc Protein and Glycoengineered Antibodies Market for Fc Protein Engineered, 2021-2030 (USD Million)
Figure 10.4 Fc Protein and Glycoengineered Antibodies Market for Fc Glycoengineered, 2021-2030 (USD Million)
Figure 10.5 Global Fc Protein and Glycoengineered Antibodies Market, 2021 and 2030: Distribution by Type of Therapy
Figure 10.6 Fc Protein and Glycoengineered Antibodies Market for Monotherapy, 2021-2030 (USD Million)
Figure 10.7 Fc Protein and Glycoengineered Antibodies Market for Combination Therapy, 2021-2030 (USD Million)
Figure 10.8 Global Fc Protein and Glycoengineered Antibodies Market, 2021 and 2030: Distribution by Therapeutic Area
Figure 10.9 Fc Protein and Glycoengineered Antibodies Market for Oncological Disorders, 2021-2030 (USD Million)
Figure 10.10 Fc Protein and Glycoengineered Antibodies Market for Rare Disorders, 2021-2030 (USD Million)
Figure 10.11 Fc Protein and Glycoengineered Antibodies Market for Dermatological Disorders, 2021-2030 (USD Million)
Figure 10.12 Fc Protein and Glycoengineered Antibodies Market for Autoimmune Disorders, 2021-2030 (USD Million)
Figure 10.13 Fc Protein and Glycoengineered Antibodies Market for Infectious Diseases, 2021-2030 (USD Million)
Figure 10.14 Fc Protein and Glycoengineered Antibodies Market for Gastrointestinal Disorders, 2021-2030 (USD Million)
Figure 10.15 Fc Protein and Glycoengineered Antibodies Market for Neurological Disorders, 2021-2030 (USD Million)
Figure 10.16 Fc Protein and Glycoengineered Antibodies Market for Pulmonary Disorders, 2021-2030 (USD Million)
Figure 10.17 Global Fc Protein and Glycoengineered Antibodies Market, 2021 and 2030: Distribution by Route of Administration
Figure 10.18 Fc Protein and Glycoengineered Antibodies Market for Intravenous Route, 2021-2030 (USD Million)
Figure 10.19 Fc Protein and Glycoengineered Antibodies Market for Subcutaneous Route, 2021-2030 (USD Million)
Figure 10.20 Fc Protein and Glycoengineered Antibodies Market for Other Routes of Administration, 2021-2030 (USD Million)
Figure 10.21 Global Fc Protein and Glycoengineered Antibodies Market, 2021 and 2030: Regional Distribution
Figure 10.22 Fc Protein and Glycoengineered Antibodies Market in North America, 2021-2030 (USD Million)
Figure 10.23 Fc Protein and Glycoengineered Antibodies Market in Europe, 2021-2030 (USD Million)
Figure 10.24 Fc Protein and Glycoengineered Antibodies Market in Asia-Pacific, 2021-2030 (USD Million)
Figure 10.25 Fc Protein and Glycoengineered Antibodies Market in Rest of the World, 2021-2030 (USD Million)
Figure 10.26 Global Fc Protein and Glycoengineered Antibodies Market (For Clinical Late-Stage Products), 2021-2030
Figure 10.27 Global Fc Protein and Glycoengineered Antibodies Market (For Commercialized Products), 2021-2030
Figure 11.1 Concluding Remarks: Current Market Overview
Figure 11.2 Concluding Remarks: Partnerships and Collaborations
Figure 11.3 Concluding Remarks: Clinical Trial Analysis
Figure 11.4 Concluding Remarks: Academic Grant Analysis
Figure 11.5 Concluding Remarks: Patent Analysis
Figure 11.6 Concluding Remarks: Market Sizing and Opportunity Analysis

List Of Tables

Table 3.1 Features of Different Isotypes of Antibodies
Table 3.2 Mechanism of Action of Antibodies against Different Target Classes
Table 3.3 Features of Engineered Fc Regions
Table 4.1 Fc Protein and Glycoengineered Antibodies: Marketed and Development Pipeline
Table 4.2 Fc Protein and Glycoengineered Antibodies: List of Developers
Table 5.1 Fc Protein and Glycoengineered Antibodies: List of Profiled Companies
Table 5.2 AbbVie: Company Snapshot
Table 5.3 Drug Profile: Skyrizi®
Table 5.4 AbbVie: Recent Developments and Future Outlook
Table 5.5 Alexion Pharmaceuticals: Company Snapshot
Table 5.6 Drug Profile: Soliris®
Table 5.7 Drug Profile: Ultomiris®
Table 5.8 Alexion Pharmaceuticals: Recent Developments and Future Outlook
Table 5.9 AstraZeneca: Company Snapshot
Table 5.10 Drug Profile: Imfinzi®
Table 5.11 Drug Profile: Fasenra®
Table 5.12 Drug Profile: Anifrolumab®
Table 5.13 Drug Profile: Nirsevimab®
Table 5.14 AstraZeneca: Recent Developments and Future Outlook
Table 5.15 Genentech / Roche: Company Snapshot
Table 5.16 Drug Profile: Gazyva®
Table 5.17 Drug Profile: Tecentriq®
Table 5.18 Drug Profile: Ocrevus®
Table 5.19 Genentech: Recent Developments and Future Outlook
Table 5.20 MacroGenics: Company Snapshot
Table 5.21 Drug Profile: Margenza
Table 5.22 Drug Profile: Enoblituzumab
Table 5.23 MacroGenics: Recent Developments and Future Outlook
Table 5.24 Kyowa Kirin: Company Snapshot
Table 5.25 Drug Profile: POTELIGEO
Table 5.26 Kyowa Kirin: Recent Developments and Future Outlook
Table 6.1 Fc Protein Engineered and Glycoengineered Antibodies: List of Partnerships and Collaborations, 2016-2021
Table 9.1 Patent Analysis: CPC Symbol Definitions
Table 9.2 Patent Analysis: List of Top CPC Symbols
Table 9.3 Patent Analysis: List of Most Popular CPC Symbols
Table 9.4 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 9.5 Patent Analysis: List of Leading Patents (by Highest Relative Valuation)
Table 9.6 Patent Analysis: List of Leading Patents (by Number of Citations)
Table 12.1 Fc Protein and Glycoengineered Antibodies: Distribution by Phase of Development
Table 12.2 Fc Protein and Glycoengineered Antibodies: Distribution by Target Disease Indication
Table 12.3 Fc Protein and Glycoengineered Antibodies: Distribution by Therapeutic Area
Table 12.4 Fc Protein and Glycoengineered Antibodies: Distribution by Target Gene
Table 12.5 Fc Protein and Glycoengineered Antibodies: Distribution by Type of Therapy
Table 12.6 Fc Protein and Glycoengineered Antibodies: Distribution by Route of Administration
Table 12.7 Fc Protein and Glycoengineered Antibodies: Distribution by Type of Antibody
Table 12.8 Fc Protein and Glycoengineered Antibodies: Distribution by Type of Fc Engineering
Table 12.9 Fc Protein and Glycoengineered Antibodies: Distribution by Impact of Fc Engineering
Table 12.10 Popular Fc Engineering Technologies: Distribution by Number of Marketed Drugs and Development Programs 
Table 12.11 Fc Protein and Glycoengineered Antibodies Developers: Distribution by Year of Establishment 
Table 12.12 Fc Protein and Glycoengineered Antibodies Developers: Distribution by Company Size
Table 12.13 Fc Protein and Glycoengineered Antibodies Developers: Distribution by Location by Headquarters
Table 12.14 AbbVie: Revenue, 2016-(Q1)2021 (USD Billion)
Table 12.15 Alexion Pharmaceuticals: Revenue, 2016-(Q1)2021 (USD Billion)
Table 12.16 AstraZeneca: Revenue, 2016-(Q1)2021 (USD Billion)
Table 12.17 Genentech / Roche : Revenue, 2016-(Q1)2021 (CHF Billion)
Table 12.18 Partnerships and Collaborations: Cumulative Trend by Year of Partnership, 2016-2021 (till April)
Table 12.19 Partnerships and Collaborations: Distribution by Type of Partnership
Table 12.20 Partnerships and Collaborations: Distribution by Year and Type of Partnership (2016-2021)
Table 12.21 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 12.22 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 12.23 Partnerships and Collaborations: Most Active Players
Table 12.24 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 12.25 Partnerships and Collaborations: Distribution by Type of Fc Engineering
Table 12.26 Partnerships and Collaborations: Distribution by Type of Partnerships, Therapeutic Area and Type of Fc Engineering
Table 12.27 Partnerships and Collaborations: Regional Distribution
Table 12.28 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 12.29 Clinical Trial Analysis: Distribution by Trial Status
Table 12.30 Clinical Trial Analysis: Distribution by Trial Registration Year, Pre-2001-2021 (till April)
Table 12.31 Clinical Trial Analysis: Distribution by Trial Status and Registration Year, Pre-2011-2021 (till April)
Table 12.32 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population
Table 12.33 Clinical Trial Analysis: Distribution by Trial Phase
Table 12.34 Clinical Trial Analysis: Distribution by Trial Phase and Enrolled Patient Population
Table 12.35 Clinical Trial Analysis: Distribution by Study Design
Table 12.36 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 12.37 Most Active Industry Players: Distribution by Number of Registered Trials
Table 12.38 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 12.39 Clinical Trial Analysis: Distribution by Drug Molecule
Table 12.40 Clinical Trial Analysis: Distribution by Target Disease Indication
Table 12.41 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 12.42 Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials
Table 12.43 Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials and Trial Status
Table 12.44 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Table 12.45 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population and Trial Status
Table 12.46 Grant Analysis: Cumulative Trend by Year of Grant Award, 2019-2021
Table 12.47 Grant Analysis: Year-wise Distribution by Amount Awarded (USD Million), 2019-2021
Table 12.48 Grant Analysis: Distribution by Administering Institute Center
Table 12.49 Grant Analysis: Distribution by Funding Institute Center
Table 12.50 Grant Analysis: Distribution by Support Period
Table 12.51 Grant Analysis: Distribution by Funding Institute Center and Support Period
Table 12.52 Grant Analysis: Distribution by Type of Grant Application
Table 12.53 Grant Analysis: Distribution by Purpose of Grant Award
Table 12.54 Grant Analysis: Distribution by Activity Code
Table 12.55 Grant Analysis: Distribution by Study Section Involved
Table 12.56 Popular NIH Departments: Distribution by Number of Grants
Table 12.57 Prominent Program Officers: Distribution by Number of Grants
Table 12.58 Grant Analysis: Distribution by Type of Recipient Organization
Table 12.59 Popular Recipient Organizations: Distribution by Number of Grants
Table 12.60 Grant Analysis: Regional Distribution of Recipient Organizations
Table 12.61 Patent Analysis: Distribution by Type of Patent
Table 12.62 Patent Analysis: Cumulative Distribution by Publication Year, 2016-2021
Table 12.63 Patent Analysis: Distribution by Issuing Authority / Patent Offices Involved
Table 12.64 Patent Analysis: Distribution by CPC Symbols
Table 12.65 Patent Analysis: Cumulative Year- wise Distribution by Type of Organization
Table 12.66 Leading Industry Players: Distribution by Number of Patents
Table 12.67 Leading Non-Industry Players: Distribution by Number of Patents
Table 12.68 Leading Individual Assignees: Distribution by Number of Patents
Table 12.69 Patent Analysis: Distribution of Patents by Age
Table 12.70 Fc Protein and Glycoengineered Antibodies: Patent Valuation
Table 12.71 Global Fc Protein and Glycoengineered Antibodies Market, 2021-2030
Table 12.72 Global Fc Protein and Glycoengineered Antibodies Market, 2021 and 2030: Distribution by Type of Fc Engineering
Table 12.73 Fc Protein and Glycoengineered Antibodies Market for Fc Protein Engineered, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.74 Fc Protein and Glycoengineered Antibodies Market for Fc Glycoengineered, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.75 Global Fc Protein and Glycoengineered Antibodies Market, 2021 and 2030: Distribution by Type of Therapy
Table 12.76 Fc Protein and Glycoengineered Antibodies Market for Monotherapy, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.77 Fc Protein and Glycoengineered Antibodies Market for Combination Therapy, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.78 Global Fc Protein and Glycoengineered Antibodies Market, 2021 and 2030: Distribution by Therapeutic Area
Table 12.79 Fc Protein and Glycoengineered Antibodies Market for Oncological Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.80 Fc Protein and Glycoengineered Antibodies Market for Rare Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.81 Fc Protein and Glycoengineered Antibodies Market for Dermatological Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.82 Fc Protein and Glycoengineered Antibodies Market for Autoimmune Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.83 Fc Protein and Glycoengineered Antibodies Market for Infectious Diseases, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.84 Fc Protein and Glycoengineered Antibodies Market for Gastrointestinal Diseases, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.85 Fc Protein and Glycoengineered Antibodies Market for Neurological Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.86 Fc Protein and Glycoengineered Antibodies Market for Pulmonary Diseases, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.87 Global Fc Protein and Glycoengineered Antibodies Market, 2021 and 2030: Distribution by Route of Administration
Table 12.88 Fc Protein and Glycoengineered Antibodies Market for Intravenous Route, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.89 Fc Protein and Glycoengineered Antibodies Market for Subcutaneous Route, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.90 Fc Protein and Glycoengineered Antibodies Market for Other Routes of Administration, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.91 Global Fc Protein and Glycoengineered Antibodies Market, 2021 and 2030: Regional Distribution
Table 12.92 Fc Protein and Glycoengineered Antibodies Market in North America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.93 Fc Protein and Glycoengineered Antibodies Market in Europe, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.94 Fc Protein and Glycoengineered Antibodies Market in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.95 Fc Protein and Glycoengineered Antibodies Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.96 Global Fc Protein and Glycoengineered Antibodies Market (For Clinical Late-Stage Products), 2021-2030 (USD Million)
Table 12.97 Global Fc Protein and Glycoengineered Antibodies Market (For Commercialized Products), 2021-2030

List Of Companies

The following companies / organizations have been mentioned in this report.

  1. AbbVie
  2. Academia Sinica
  3. AGC Biologics 
  4. Agenus
  5. Airway Therapeutics
  6. Akesobio
  7. Albert Einstein College of Medicine
  8. Alexion Pharmaceuticals
  9. Amgen
  10. argenx
  11. AstraZeneca
  12. BeiGene
  13. BIOCAD
  14. Biogen
  15. Boehringer Ingelheim
  16. Bristol-Myers Squibb
  17. Canadian Cancer Trials Group
  18. Cantargia
  19. CATO SMS
  20. Celgene
  21. Celldex Therapeutics
  22. Chia Tai Tianqing Pharmaceutical 
  23. Chinese Academy of Sciences
  24. Chugai Pharmaceuticals
  25. CSL Behring
  26. Daiichi Sankyo
  27. Dana-Farber Cancer Institute
  28. Duke University
  29. Eli Lilly
  30. Emory University
  31. EVERSANA
  32. Five Prime Therapeutics
  33. Fountain Biopharma
  34. Genentech
  35. Genmab
  36. German CLL Study Group
  37. Gilead Sciences
  38. Glycotope
  39. GlaxoSmithKline
  40. Guangzhou Development District
  41. Hoosier Cancer Research Network
  42. Horizon Therapeutics
  43. Humanigen
  44. I-Mab Biopharma
  45. Immunicum
  46. Incyte
  47. Janssen
  48. Junshi Biosciences
  49. Kolltan Pharmaceuticals 
  50. Kyowa Kirin
  51. Leland Stanford Junior University
  52. LEO Pharma
  53. Ludwig Institute for Cancer Research
  54. MD Anderson Cancer Center
  55. MacroGenics
  56. Memorial Sloan Kettering Cancer Center
  57. Menarini
  58. MorphoSys
  59. National Institute of Allergy and Infectious Diseases (NIAID)
  60. National Institutes of Health Clinical Center
  61. NGM Biopharmaceuticals
  62. Novartis
  63. Oneness Biotech
  64. ONK Therapeutics
  65. PAREXEL
  66. Patheon
  67. Provention Bio
  68. Roche
  69. Samsung Biologics
  70. Sanofi
  71. Seagen
  72. Seoul National University Hospital
  73. Sino Biopharmaceutical
  74. SYNIMMUNE
  75. TG Therapeutics
  76. The Rockefeller University
  77. Tillotts Pharma 
  78. Tiziana Life Sciences
  79. TRIANNI
  80. United BioPharma
  81. University of California, Los Angeles (UCLA)
  82. University of Leicester
  83. University of Maryland
  84. University of Pennsylvania
  85. University of Texas
  86. University of Virginia
  87. Viela Bio
  88. Vir Biotechnology
  89. Visterra
  90. Vitaeris
  91. Washington University
  92. WuXi Biologics
  93. Xencor
  94. Zai Lab
  95. Zymeworks

PRICING DETAILS

USD 5,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com